New
Hot
ColumnsPfizer stock dips on Q4 revenue miss, FY23 outlook sees COVID products decline
Welcome to click to follow~~
$Pfizer(PFE.US$ is trading lower premarket on Tuesday after mixed Q4 results and a full year 2023 outlook which is seen lower than expected.
Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating estimates while revenue increased +2% to $24.29B but missed analysts expectations.
COVID vaccine, developed with partner $BioNTech(BNTX.US$, Comirnaty direct sales and alliance revenues declined -9% Y/...
$Pfizer(PFE.US$ is trading lower premarket on Tuesday after mixed Q4 results and a full year 2023 outlook which is seen lower than expected.
Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating estimates while revenue increased +2% to $24.29B but missed analysts expectations.
COVID vaccine, developed with partner $BioNTech(BNTX.US$, Comirnaty direct sales and alliance revenues declined -9% Y/...
2
Pfizer (PFE) Earnings - Gloomy Road Ahead
Pfizer (PFE) just announced their Q4’2022 EPS of $1.14, beating the analysts’ estimate of $1.07. They booked a revenue of $100.3 bil for FY2022 thanks to the Covid vaccine and antiviral sales which contributed more than half of it. However, the fun ends here because they are forecasting up to a 33% decline in their revenue for FY2023 as the Covid pandemic eases and hence the plunge of the demand for its vaccine.
In an attempt to diversify from the Covid b...
In an attempt to diversify from the Covid b...
4
2
PFE Earnings
- Q4 Non-GAAP EPS of $1.14 beats by $0.10.
- Revenue of $24.3B (+1.9% Y/Y) misses by $100M.
2023 Guidance:
- Rev of $67.0 to $71.0 Billion vs. $74.23B consensus
- Adjusted Diluted EPS of $3.25 to $3.45 vs $4.38 consensus
Revenues from COVID-19 products expected to grow in 2024 after reaching a low point in 2023 due to significant government supply on hand to start the year.
- Revenue of $24.3B (+1.9% Y/Y) misses by $100M.
2023 Guidance:
- Rev of $67.0 to $71.0 Billion vs. $74.23B consensus
- Adjusted Diluted EPS of $3.25 to $3.45 vs $4.38 consensus
Revenues from COVID-19 products expected to grow in 2024 after reaching a low point in 2023 due to significant government supply on hand to start the year.
2